Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 34.61.
Forward PE Ratio (34.61) = Close Price ($92.34) / Consensus Forward EPS ($2.67)
FORWARD PE RATIO
34.61
SECTOR MEDIAN · HEALTHCARE
19.91
median of 68 covered companies
CURRENT VS SECTOR MEDIAN
+73.79%
vs the sector median at left
DexCom, Inc.
Market Cap
$34.85B
Forward PE Ratio
34.61
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| DexCom, Inc. (DXCM) | $34.85B | 34.61 |
| GE HealthCare Technologies Inc. (GEHC)vs › | $33.80B | 15.19 |
| ResMed Inc. (RMD)vs › | $33.58B | 20.81 |
| Zoetis Inc. (ZTS)vs › | $32.59B | 12.35 |
| Centene Corp. (CNC)vs › | $32.12B | 13.54 |
| Biogen Inc. (BIIB)vs › | $32.03B | 17.40 |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $31.61B | 36.30 |
| Waters Corporation (WAT)vs › | $30.72B | 28.18 |
| BioNTech SE (BNTX)vs › | $29.28B | N/A |
| Medline Inc. (MDLN)vs › | $28.97B | 22.71 |
Trailing P/E
36.5
reported TTM EPS
Forward P/E
34.6
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $2.67 implies +5.5% EPS growth vs the reported trailing $2.53.
At today's $92.34 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $2.67 | $2.48 – $2.73 | 15 | 34.6x |
| 2027-12-31 | $3.12 | $2.87 – $3.33 | 16 | 29.6x |
| 2028-12-31 | $3.72 | $2.91 – $4.01 | 7 | 24.8x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
